LLY

877.96

-2.32%↓

JNJ

240.27

+0.43%↑

ABBV

209.68

-0.75%↓

NVS

148.25

-0.86%↓

MRK

119.68

+0.62%↑

LLY

877.96

-2.32%↓

JNJ

240.27

+0.43%↑

ABBV

209.68

-0.75%↓

NVS

148.25

-0.86%↓

MRK

119.68

+0.62%↑

LLY

877.96

-2.32%↓

JNJ

240.27

+0.43%↑

ABBV

209.68

-0.75%↓

NVS

148.25

-0.86%↓

MRK

119.68

+0.62%↑

LLY

877.96

-2.32%↓

JNJ

240.27

+0.43%↑

ABBV

209.68

-0.75%↓

NVS

148.25

-0.86%↓

MRK

119.68

+0.62%↑

LLY

877.96

-2.32%↓

JNJ

240.27

+0.43%↑

ABBV

209.68

-0.75%↓

NVS

148.25

-0.86%↓

MRK

119.68

+0.62%↑

Home・Lista de Ações・Arbutus Biopharma Corp

Arbutus Biopharma Corp

Fechado

4.29 -4.24

Comprar Vender

Visão Geral

Variação de preço das ações

24h

Atual

Mín

4.29

Máximo

4.33

Indicadores-chave
By Trading Economics
Rendimento	4M -3.8M
Vendas	522K 1.1M
EPS	-0.014
Margem de lucro	-357.374
Funcionários	44
EBITDA	-1.1M -8.8M

Dividendos
By Dow Jones
Próximos Ganhos	13 de mai. de 2026

Estatísticas de Mercado
By TradingEconomics
Capitalização de Mercado	12M 851M
Abertura anterior	8.53
Fecho anterior	4.29

Pontuação Técnica

By Trading Central

Confiança

Weak Bearish Evidence

3.255 / 3.365 Suporte e Resistência

Arbutus Biopharma Corp Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

27 de mar. de 2026, 17:33 UTC

Notícias Principais

ECB Should Not Rush Its Response to Iran Conflict, Says Schnabel -- Update

27 de mar. de 2026, 17:00 UTC

Notícias Principais

ECB Shouldn't Rush Its Response to Iran Conflict, Schnabel Says

27 de mar. de 2026, 16:03 UTC

Notícias Principais

Fertilizer Maker Yara Warns Farmers Are Being Squeezed by Price Surge Amid War -- Commodities Roundup

29 de mar. de 2026, 23:47 UTC

Conversa de Mercado

Notícias Principais

Gold Falls Amid Rising Inflation Fears -- Market Talk

29 de mar. de 2026, 23:46 UTC

Conversa de Mercado

Notícias Principais

Nikkei May Fall on Fears About Shortage of Petrochemical Products -- Market Talk

29 de mar. de 2026, 23:35 UTC

Conversa de Mercado

Notícias Principais

Oil Rises on Supply-Disruption Concerns Spurred by Widening Mideast Conflict -- Market Talk

29 de mar. de 2026, 23:23 UTC

Conversa de Mercado

Australia's National Cabinet to Avoid Covid-Style Measures -- Market Talk

29 de mar. de 2026, 22:34 UTC

Conversa de Mercado

Macroeconomic Tailwind for Warehouse Dissipates -- Market Talk

29 de mar. de 2026, 22:09 UTC

Conversa de Mercado

Amplitude's Next Well "Effectively a Must-Win" for Growth Thesis -- Market Talk

29 de mar. de 2026, 21:06 UTC

Conversa de Mercado

Notícias Principais

Australia's Economy Could Already Be Contracting Amid Oil Shock -- Market Talk

29 de mar. de 2026, 21:03 UTC

Conversa de Mercado

Australia's Government Wants to Avoid Heavy Handed Oil Shock Response -- Market Talk

29 de mar. de 2026, 21:01 UTC

Conversa de Mercado

Notícias Principais

Australian National Cabinet Meeting to Focus on Oil Supply -- Market Talk

29 de mar. de 2026, 09:30 UTC

Aquisições, Fusões, Aquisições de Empresas

Food Mega-Mergers Hardly Ever Work. Could McCormick-Unilever Be Different? -- Heard on the Street -- WSJ

28 de mar. de 2026, 08:20 UTC

Conversa de Mercado

Health Care Roundup: Market Talk

27 de mar. de 2026, 20:50 UTC

Conversa de Mercado

Health Care Roundup: Market Talk

27 de mar. de 2026, 19:16 UTC

Conversa de Mercado

Notícias Principais

Oil Futures Rise On Uncertainty Ahead of Weekend -- Market Talk

27 de mar. de 2026, 19:07 UTC

Conversa de Mercado

U.S. Natural Gas Gains As April Contract Expires -- Market Talk

27 de mar. de 2026, 19:04 UTC

Conversa de Mercado

Gold Rises But Can't Finish the Week Positive -- Market Talk

27 de mar. de 2026, 19:03 UTC

Conversa de Mercado

Notícias Principais

Global Forex and Fixed Income Roundup: Market Talk

27 de mar. de 2026, 19:02 UTC

Conversa de Mercado

Notícias Principais

Among Central Banks, Canada Has Room to Handle Oil Inflation -- Market Talk

27 de mar. de 2026, 18:12 UTC

Conversa de Mercado

Foreign Fuels and Feedstocks to Get RINs Until 2028 -- Market Talk

27 de mar. de 2026, 17:36 UTC

Notícias Principais

The Iran War and Oil Prices Bring Risk of Deeper Market Lows. There Are Echoes of 2008. -- Barrons.com

27 de mar. de 2026, 17:34 UTC

Conversa de Mercado

Aquisições, Fusões, Aquisições de Empresas

Delivery Hero Shares Bounce as Stake-Sale Report Whets Investor Appetites -- Market Talk

27 de mar. de 2026, 17:29 UTC

Conversa de Mercado

U.S. Oil Rig Count Falls By 5 to 409 -- Market Talk

27 de mar. de 2026, 16:38 UTC

Conversa de Mercado

Carnival's Outlook Assumes Oil Prices Will Come Down -- Market Talk

27 de mar. de 2026, 16:32 UTC

Conversa de Mercado

Notícias Principais

Chinese Exposure to Higher Energy Costs Seen as Limited -- Market Talk

27 de mar. de 2026, 16:20 UTC

Conversa de Mercado

Health Care Roundup: Market Talk

27 de mar. de 2026, 15:43 UTC

Conversa de Mercado

Notícias Principais

Hormuz Closure Sends Tanker Rates to Record Highs -- Market Talk

27 de mar. de 2026, 15:25 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

27 de mar. de 2026, 15:25 UTC

Conversa de Mercado

Swiss Franc Dented by Rising European Yields, SNB Intervention Threats -- Market Talk

Comparação entre Pares

Variação de preço

Arbutus Biopharma Corp Previsão

Consenso de Avaliação

By TipRanks

0 ratings

Comprar

Manter

Vender

Com base em 0 analistas que deram avaliações de ações para Arbutus Biopharma Corp - Dist nos últimos 3 meses.

Pontuação Técnica

By Trading Central

3.255 / 3.365Suporte e Resistência

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

Sobre Arbutus Biopharma Corp

Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression. The company's research and development programs include AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune system; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has licensing agreements with Gritstone Oncology, Inc; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Barinthus Biotherapeutics plc to evaluate VTP-300. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.